Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Rosacea

Rosacea

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Rosacea

49 trials tracked for Rosacea: 31 in phase 3 or 4 and 2 with published results. The most-cited published study has 53 citations.

49Trials tracked
31Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 9 Phase 3 22 Phase 2 11 Phase 1 2 Other / NA 5
  1. Phase 3 Patient-Reported Outcome Of Facial Erythema (PROOF) Completed · 53 cited
  2. Phase 3 Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel Completed · 40 cited
  3. Phase 4 Mirvaso in Use Study Completed
  4. Phase 4 MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea. Completed
  5. Phase 4 Internet Surveys and Their Impact on Adherence for Rosacea Completed
  6. Phase 4 Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea Completed
Show 43 more trials
  1. Phase 4 Oracea Soolantra Association in Participants With Severe Rosacea Completed
  2. Phase 4 Photodynamic Therapy for Papulopustular Rosacea Completed
  3. Phase 4 ORCA - Oracea® for Rosacea: A Community-based Assessment Completed
  4. Phase 4 Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo Completed
  5. Phase 4 Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo Completed
  6. Phase 3 Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea Completed
  7. Phase 3 A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea Completed
  8. Phase 3 Azelaic Acid on Demodex Counts in Rosacea Completed
  9. Phase 3 A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea Completed
  10. Phase 3 Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea Completed
  11. Phase 3 A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea Completed
  12. Phase 3 Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face Completed
  13. Phase 3 Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea Completed
  14. Phase 3 Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea Completed
  15. Phase 3 An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea Completed
  16. Phase 3 A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream" Completed
  17. Phase 3 Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle Completed
  18. Phase 3 Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle Completed
  19. Phase 3 Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea Completed
  20. Phase 3 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Completed
  21. Phase 3 Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea Completed
  22. Phase 3 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea Completed
  23. Phase 3 Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Completed
  24. Phase 3 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Completed
  25. Phase 3 Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea Completed
  26. Phase 2 Effect of CD07805/47 Gel in Rosacea Flushing Completed
  27. Phase 2 AGN-199201 for the Treatment of Erythema With Rosacea Completed
  28. Phase 2 A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea Completed
  29. Phase 2 Therapeutic Effects of Topical Herbal Medicine -Rhubarb Ointment on Rosacea Completed
  30. Phase 2 A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules Completed
  31. Phase 2 A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea Completed
  32. Phase 2 Rosacea and Ivermectin Completed
  33. Phase 2 A Study to Assess the Efficacy, Safety and Tolerability of DFD-04 Completed
  34. Phase 2 A Study of DER 45-EV Gel to Treat Rosacea Completed
  35. Phase 2 Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation. Completed
  36. Phase 2 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Completed
  37. Phase 1 Effects of Aminocaproic Acid (ACA) on Rosacea-specific Inflammation Completed
  38. Phase 1 Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea Completed
  39. N/A Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale Completed
  40. N/A Combination Gel and Vascular ND in Mild to Moderate Rosacea Completed
  41. N/A Evaluation of Cutera Excel V™ Laser With Green Genesis and Micro-Lens Array (MLA)Attachment Completed
  42. N/A Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE) Completed
  43. N/A Safety and Efficacy of the Luxe Device to Treat Facial Wrinkles and Rosacea Completed

Showing the 49 most-cited and recently-updated of 49 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Rosacea: what the trials found

Ivermectin has demonstrated significant efficacy in reducing inflammatory lesion counts, with one study showing a reduction of approximately 73% to 80% at week 12 3 and another reporting mean reductions exceeding 55% 16. Additionally, ivermectin was evaluated in early-phase trials 1.

Brimonidine (including 0.33% gel formulations) has shown clinical utility for managing symptoms; it achieved a success rate of 53% on the Investigator's Global Assessment scale 7 and significantly improved patient satisfaction scores compared to placebo 11. Brimonidine also demonstrated significant treatment success rates at various time points in Phase 3 trials 21.

Azelaic acid (including foam formulations) consistently reduces inflammatory lesion counts, with reductions ranging from approximately 49% to 69% across multiple studies [19, 20, 22]. Specifically, generic azelaic acid foam showed a statistically significant reduction in papules and pustules at week 12 22.

Oxymetazoline hydrochloride was shown to improve clinical erythema; one study reported success rates of up to 78% for patients achieving a 2-grade improvement on the Clinician Erythema Assessment scale 15. Other studies noted improvements in erythema scores and low rates of serious adverse events with oxymetazoline [4, 17].

Doxycycline was evaluated as a monotherapy; while some trials showed significant responder numbers at endpoints 10, other data indicated varying levels of improvement in Investigator's Global Assessment (IGA) and Clinician's Erythema Assessment (CEA) scores [8, 9].

Omiganan (CLS001) demonstrated statistically significant reductions in inflammatory lesion counts and a higher percentage of patients achieving a 2-grade IGA reduction compared to placebo in one trial 13, though results were not statistically significant in another study 14.

Recent results — preliminary, needs further review

  • Ivermectin was evaluated in a Phase 2 trial (N=30) as a new intervention for the condition 1.

For the clinician treating this condition

  • Ivermectin and Azelaic acid are established options for reducing inflammatory lesion counts, with both showing substantial percentage reductions from baseline [3, 16, 19, 20, 22].
  • Brimonidine is an established option for managing facial redness and improving patient satisfaction scores [11, 21].
  • Oxymetazoline hydrochloride can be utilized to improve clinical erythema scores [15, 17].
  • Omiganan (CLS001) shows evidence of reducing inflammatory lesion counts, though results across trials were not consistent in significance [13, 14].

AI synthesis of 11 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.